1. Media & Marketing

Drug Channels News Roundup, April 2025: Amazon Rx Update, Express Scripts’ Spend Trends, Gold Cards, and CMS Acronym Absurdity

Written by Posted on Less than 0 min read

Spring has officially arrived at Drug Channels’ worldwide headquarters in beautiful downtown Philadelphia. (Photo proof at right.) So, scurry over to this month’s curated crop of noteworthy news:

  • Amazon Pharmacy is still coming for retail pharmacy
  • Express Scripts revives its long-lost drug trend report
  • Prior authorization gold cards: Progress or peril?

Plus, MPPP or not MPPP? That is the question.

P.S. Join nearly 63,000 of your peers who follow me on LinkedIn for daily insights, links to neat stuff, and sharp commentary from the ever-engaged DCI community.

Live from Asembia’s AXS25 Summit: The DCI team is on-site! Swing by booth #1601 at 4 p.m. today for our “Ask Adam Anything” (#AAA) session.

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

How Field Reimbursement Services Help Overcome Coverage Barriers and Improve Patient Outcomes

Today’s guest post comes from Kimberley Chiang, Vice President of Biopharma Commercial Solutions at CoverMyMeds Kimberley highlghts the crucial roles of field reimbursement managers in removing access and reimbursement barriers. She then identifies the keys to successful implementation of field reimbursement services. To learn more, register for CoverMyMeds’ November 13, 2024, webinar: Specialty Therapies & […]
2 min read
0
  1. Trends & External Forces

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers’ preparation. To learn more, register […]
2 min read
0
  1. Trends & External Forces

The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents

Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—although revenues remain highly concentrated. We have identified nearly 1,800 dispensing sites with specialty pharmacy accreditation—about 40% of which are owned by hospitals, physician practices, and other healthcare providers. Alas, specialty pharmacies owned by the three largest […]
2 min read
0
  1. Data & Insights

From Data Gaps to Revenue Gains: Harnessing the Power of Comprehensive Data to Drive GTN

Today’s guest post comes from Thomas Luby, Sr. Vice President, Business Development at PHIL. Thomas discusses the challenges brands face as they manage gross-to-net (GTN) performance while simultaneously enhancing patient access and adherence. He lists the key performance indicators that can help brands improve GTN. To learn more, watch PHIL’s free on-demand webinar: Four Patient Access […]
2 min read
0
  1. Data & Insights

Copay Accumulator and Maximizer Update: Adoption Expands as Legal Barriers Grow (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Click here to see the original post from February 2024. It’s Valentine’s Day—and commercial plan sponsors remain smitten with copay accumulators and maximizers. Our latest update finds that as of late […]
2 min read
0
  1. Trends & External Forces

Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A May 2024 Update

It’s time for Drug Channels’ annual update of vertical integration among insurers, PBMs, specialty pharmacies, and providers within U.S. drug channels. Below you’ll find our latest illustration of the major vertical business relationships among the largest companies along with some of the notable activity since our previous update. These organizations continue to exert greater control […]
2 min read
0
  1. Trends & External Forces

NOW AVAILABLE: 2024–25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

I am pleased to announce Drug Channels Institute’s new 2024–25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, available for purchase and immediate download. Download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) Review pricing/license options and download the full 2024-25 report We’re offering special discounted […]
2 min read
0
  1. Trends & External Forces

The 340B Program Reached $66 Billion in 2023—Up 23% vs. 2022: Analyzing the Numbers and HRSA’s Curious Actions

Reality has again failed to support the spin surrounding the 340B Drug Pricing Program. For 2023, discounted purchases under the 340B program reached a record $66.3 billion—an astounding $12.6 billion (+23.4%) higher than its 2022 counterpart. The gross-to-net difference between list prices and discounted 340B purchases also grew, to $57.8 billion (+$5.5 billion). 340B purchases […]
2 min read
0
  1. Data & Insights

White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s Drug Channels Outlook 2025 live video webinar. During the webinar, I’ll share some thoughts on how vertical integration will affect the buy-and-bill channel. Click here to see the original post from September 2024. Time for DCI’s annual update on the channels for provider-administered […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, June 2024: Cordavis Humira Update, OptumRx’s New Biosim Biz, Generic Drugs’ Wild Ride, IRA Predictions, and Dr. G on Med School

Happy 248th birthday, America! Before you launch your July 4 festivities, Drug Channels offers some fireworks of its own: CVS Health’s Cordavis is winning the Humira biosimilar battle Meet NUVAILA, OptumRx’s new biosimilar procurement business The acquisition cost revolution hits a speedbump following NADAC volatility Five predictions about the IRA’s impact on the drug channel […]
2 min read
0
  1. Department: HBC

NOW AVAILABLE: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

I am pleased to announce that Drug Channels Institute’s new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. Download a free 30-page report overview—including key industry trends, What’s New in this edition, the Table of Contents, and a List of Exhibits Read the press release: […]
4 min read
0
  1. Data & Insights

White Bagging Update 2023: Saving Money or Shifting Costs? (rerun)

This week, I’m rerunning some popular posts while I prepare for Fiday’s Drug Channels Outlook 2024 live video webinar. Click here to see the original post from September 2023. Time for our annual update on the channels for provider-administered drugs. For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution […]
2 min read
0
  1. Department: Food

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you: Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble Optum Rx joins the private label biosimilar bandwagon Biosimilars boom for provider-administered drugs Fresh evidence of how copay accumulators hurt patients […]
2 min read
0
  1. Department: HBC

Independents Outshine PBMs in Manufacturers’ Exclusive Specialty Pharmacy Networks (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Click here to see the original post from April 2024. Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 Specialty Pharmacies of 2023: […]
2 min read
0
  1. Trends & External Forces

Transparency vs. Reality: Troubling Lessons from PBM Disclosure Laws

Last week, President Trump signed yet another executive order, this time promising to make healthcare pricing more transparent. While this marks another federal push for disclosure, states have already been quite active in this space. Since 2017, 24 states have passed 38 laws targeting healthcare transparency, with a strong focus on unraveling the complex economics […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, February 2024: Pharmacy Shakeout Update, High Drug Prices, 340B Realities, MDs vs. Pharmacists, and Foo Fighters

February is longer than usual this year, which means that you’ll have extra time to leap into our monthly curated selection of noteworthy news. In this issue: An update on the retail pharmacy shakeout Arguing for high drug prices A leading researcher provides a 340B reality check Physicians don’t want pharmacists getting uppity Plus, Dave […]
2 min read
0
  1. Trends & External Forces

Another IRA Surprise: Part B Coinsurance Inflation Adjustments Are Increasing Patient Costs (rerun)

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The article below highlights an underappreciated consequence of the Inflation Reduction Act’s inflation rebates for Medicare Part B drugs. Last night, I posted an updated analysis showing that the volatility […]
3 min read
0
  1. Media & Marketing

Drug Channels News Roundup, July 2024: My $0.02 on FTC’s PBM Report, GoodRx & Humira, Averon = CVS + Cardinal, IRA vs. 340B, and My Favorite Chart

Bello! The hot and hazy days of summer are here. Go for a swim to cool off and then enjoy this refreshing selection of articles chosen by Drug Channels para tu. Did the FTC’s compelling interim report prove its case? GoodRx joins the Humira biosimilar price war with Boehringer Ingelheim Averon revealed to be a […]
2 min read
0
  1. Trends & External Forces

The Top 15 U.S. Pharmacies of 2023: Market Shares and Revenues at the Biggest Chains and PBMs

Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 15th edition of our popular and comprehensive examination of the entire U.S. drug pricing, reimbursement, and dispensing system. For 2023, DCI estimates that U.S. prescription dispensing revenues reached $621 billion in 2023, driven by […]
2 min read
0
  1. Merchandising

Available for Preorder: The 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 8, 2024, Drug Channels Institute will release our 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our fifteenth edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. 9 chapters, 350+ pages, 178 exhibits, 750+ endnotes: There is nothing else available that comes close […]
2 min read
0
Next